INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease
The Phase 1 INTERCEPT-AD study provided safety, tolerability, dosing, and target engagement data that supported the design of the ongoing ALTITUDE-AD study (NCT06335173).
Authors
- Reisa Anne Sperling (ORCID: https://orcid.org/0000-0003-1535-6133)
- Stephen Salloway (ORCID: https://orcid.org/0000-0002-2631-0942)
- Lawrence S. Honig (ORCID: https://orcid.org/0000-0002-9703-2265)
- Kimball Johnson
- Todd Feaster
- Mirjam N. Trame (ORCID: https://orcid.org/0000-0002-1030-4986)
- Vladimir Skljarevski
- Hao Zhang (ORCID: https://orcid.org/0000-0002-7377-0589)
- Erika N. Cline (ORCID: https://orcid.org/0000-0001-8062-4312)
- Michael Dodds (ORCID: https://orcid.org/0000-0002-0135-7840)
- Jasna Jerecı̀ć
- Eric Siemers
- Karen Sundell
- Gopalan Sethuraman
Institutions
- Harvard University (US)
- Princeton University (US)
- Brown University (US)
- Columbia University Irving Medical Center (US)
- Butler Hospital (US)
- Acumen Pharmaceuticals (United States) (US)
- iResearch Atlanta (US)
Publication Details
- Journal
- The Journal of Prevention of Alzheimer s Disease
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.tjpad.2024.100005
- Citations
- 6
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.99